Register Login

Idarucizumab for Dabigatran Reversal Approved

On Friday, October 16, the FDA approved idarucizumab (Praxbind) as an effective reversal agent for the oral direct thrombin inhibitor, dabigatran (Pradaxa). Click here tor the press release. Thanks to Dr. Paul Riley, Stago-US, for this heads-up.

Comments (0)
Anticoagulant Therapy

No comments here.

Leave a Reply